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Table 1S. Included reviews. 
First author (acronym) Journal Journal impact factor Year of publication PubMed ID Studies included Patients included 
Abdel-Latif Arch Intern Med >10 2007 17533201 18 999 
Alvarez Clin Res Cardiol 1-5 2012 23052331 35 2472 
Bai Ageing Res Rev 5-10 2010 20471500 10 850 
Brunskill Eur J Heart Fail 5-10 2009 19654139 21 1091 
Cheng Heart Lung Circ 1-5 2013 23806195 5 210 
Clifford PLoS One 1-5 2012 22655042 33 1765 
de Jong Circ Cardiovasc Interv 5-10 2014 24668227 30 2037 
Delewi Heart 5-10 2012 22875736 24 1624 
Delewi Eur Heart J >10 2013 24026778 16 1641 
Donndorf J Thorac Cardiovasc Surg 1-5 2011 21376346 6 179 
Fan Cardiovasc Drugs Ther 1-5 2007 18000749 6 320 
Fisher PLoS One 1-5 2013 23840302 9 659 
Fisher Cochrane Database Syst Rev 5-10 2014 24777540 23 1255 
Henry J Am Coll Cardiol >10 2007 17825712 2 532 
Hristow J Cell Mol Med 1-5 2006 16989732 5 482 
Ince Heart 5-10 2007 17761504 7 325 
Jeevanantham Circulation >10 2012 22730444 50 2625 
Jiang Expert Opin Biol Ther 1-5 2010 20384520 18 980 
Jiang Stem Cell Res 1-5 2012 22640927 6 365 
Kandala Am J Cardiol 1-5 2013 23623290 10 519 
Kang Clin Ther 1-5 2007 18158081 7 364 
Kang Coron Artery Dis 1-5 2008 18607170 6 517 
Kuswardhani Acta Med Indones <1 2011 21979282 10 906 
Li Can J Cardiol 1-5 2013 23465346 5 381 
Lipinski J Am Coll Cardiol >10 2007 17964040 10 698 
Martin-Rendon Eur Heart J >10 2008 18523058 13 811 
Moazzami Cochrane Database Syst Rev 5-10 2013 23728682 7 354 
Nowbar (DAMASCENE) BMJ >10 2014 24778175 49 NA 
Singh Clin Cardiol 1-5 2009 19353705 7 516 
Sun Clin Cardiol 1-5 2010 20513068 11 832 
Takagi Int J Cardiol 5-10 2011 21641056 15 877 
Tian Atherosclerosis 1-5 2014 24530783 11 492 
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Wen Expert Opin Biol Ther 1-5 2011 21388335 8 307 
Wen Int J Clin Pract 1-5 2011 21762310 7 343 
Xu Can J Cardiol 1-5 2014 24726092 19 886 
Zhang Clin Cardiol 1-5 2009 19685520 7 660 
Zhang Int J Cardiol 5-10 2009 18644638 6 525 
Zhang Clin Cardiol 1-5 2010 20556805 8 725 
Zhao Expert Opin Biol Ther 1-5 2011 21981749 10 422 
Zimmet Eur J Heart Fail 5-10 2011 22065869 29 1830 
Zohlnhöfer J Am Coll Cardiol >10 2008 18402895 10 445 
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Table 2S. Additional features of included reviews. 
First author (acronym) Year of publication Included studies  Setting Therapy Country of corresponding author Number of authors 
Abdel-Latif 2007 Non-RCTs and RCTS IHD/HF BMSC USA 9 
Alvarez 2012 Non-RCTs and RCTS IHD/HF Any type of SC USA 9 
Bai 2010 RTCs AMI BMSC China 3 
Brunskill 2009 RTCs IHD/HF BMSC UK 5 
Cheng 2013 RTCs IHD/HF Any type of SC China 3 
Clifford 2012 RTCs AMI BMSC UK 8 
de Jong 2014 RTCs AMI BMSC Netherlands 5 
Delewi 2012 RTCs AMI BMSC Netherlands 6 
Delewi 2013 RTCs AMI BMSC Netherlands 26 
Donndorf 2011 Non-RCTs and RCTS IHD/HF BMSC Germany 7 
Fan 2007 RTCs AMI G-CSF China 4 
Fisher 2013 RTCs IHD/HF BMSC UK 5 
Fisher 2014 RTCs IHD/HF BMSC UK 6 
Henry 2007 RTCs IHD/HF Other USA 8 
Hristow 2006 RTCs AMI BMSC Germany 4 
Ince 2007 RTCs AMI G-CSF Germany 8 
Jeevanantham 2012 Non-RCTs and RCTS IHD/HF BMSC USA 6 
Jiang 2010 RTCs IHD/HF Any type of SC China 14 
Jiang 2012 RTCs AMI BMSC China 3 
Kandala 2013 RTCs IHD/HF BMSC USA 6 
Kang 2007 RTCs IHD/HF G-CSF China 4 
Kang 2008 RTCs AMI BMSC China 4 
Kuswardhani 2011 RTCs AMI BMSC China 4 
Li 2013 RTCs IHD/HF Any type of SC China 6 
Lipinski 2007 RTCs AMI BMSC Italy 11 
Martin-Rendon 2008 RTCs AMI BMSC UK 6 
Moazzami 2013 RTCs AMI G-CSF USA 3 
Nowbar (DAMASCENE) 2014 RTCs IHD/HF BMSC UK 9 
Singh 2009 RTCs AMI BMSC USA 7 
Sun 2010 Non-RCTs and RCTS AMI Any type of SC China 4 
Takagi 2011 RTCs AMI Any type of SC Japan 2 
Tian 2014 RTCs IHD/HF BMSC China 5 
Wen 2011 RTCs IHD/HF BMSC China 5 
Wen 2011 RTCs IHD/HF BMSC China 4 
9 
Xu 2014 RTCs IHD/HF BMSC China 5 
Zhang 2009 RTCs AMI BMSC China 9 
Zhang 2009 RTCs AMI BMSC China 7 
Zhang 2010 RTCs AMI BMSC China 9 
Zhao 2011 RTCs IHD/HF BMSC China 2 
Zimmet 2011 RTCs AMI 2 Australia 8 
Zohlnhöfer 2008 RTCs AMI G-CSF Germany 9 
 
AMI=acute myocardial infarction; BMSC=bone marrow-derived stem cell; G-CSF=granulocyte-colony stimulating factor; HF=heart failure; 
IHD=ischemic heart disease; Non-RCTs=non-randomized clinical trials; RCTs=randomized clinical trials; SC=stem cell 
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Effect estimates for 
LVEF 
Effect estimates for death 
Yearly WOS 
citations 
Abdel-Latif 2007 10 
BMSC are associated with improvements in cardiac function 
parameters in patients with acute and chronic IHD. 
3.66 (1.93 to 5.40) NA 68,9 
Alvarez 2012 3 
Most adverse events associated with cell therapy occur 
during intracoronary infusion and G-CSF administration. 
NA NA 0,0 
Bai 2010 9 
BMSC are associated with improvements in cardiac function 
parameters in patients with AMI, especially in the elderly, 
diabetics, and women. 
3.79 (2.4 to 5.7) NA 1,8 
Brunskill 2009 10 
BMSC are associated with improvements in cardiac function 
parameters in patients with AMI, especially when delivered 
with intramyocardial injection and with lower baseline LVEF. 
3.71 (2.15 to 5.26) NA 5,1 
Cheng 2013 9 
Stem cells are not associated with changes in prognosis or 
cardiac function parameters, but may improve symptoms. 
0.02 (-0.31 to 0.35) RR=2.27 (0.60-8.62) 1,4 
Clifford 2012 11 
BMSC effects on cardiac function parameters seem to be 
greater in patients with AMI when more than 10^8 cells are 
injected and with lower baseline LVEF. 
3.26 (1.12 to 4.40) RR=0.70 (0.40-1.21) 6,9 
de Jong 2014 10 
BMSC are not associated with significant effects on 
prognosis, or MRI-derived cardiac function parameters. 
2.10 (0.68 to 3.52) 
OR=0.68 (0.36-1.31) for BMMNC, 
OR=0.50 (0.09-2.67) for BM 
progenitor cells, and OR=3.18 
(0.13-81.01) for MSC 
NA 
Delewi 2012 10 
BMSC are associated with improvements in prognosis and 
cardiac fucntion parameters. 
2.23 (1.00 to 3.47) RR=0.60 (0.38-1.08) 3,5 
Delewi 2013 #RIF! 
BMSC are associated with  improvements in cardiac function 
parameters, especially in younger patients and those with 
lower baseline LVEF. 
2.55 (1.83 to 3.26) NA 6,8 
Donndorf 2011 10 
BMSC are associated with improvements in cardiac function 
parameters in patients undergoing CABG. 
5.40 (1.36 to 9.44) NA 6,2 
Fan 2007 10 
G-CSF is not associated with changes in cardiac function 
parameters in patients with AMI. 
2.27 (-3.41 to 7.94) NA 2,0 
Fisher 2013 9 
BMSC are associated with improvements in prognosis, 
cardiac function parameters, and symptoms. 
3.47 (1.88 to 5.06) RR=0.33 (0.17-0.65) 4,3 
11 
Fisher 2014 11 
According to studies with average to low internal validity, 
BMSC appear to improve prognosis, cardiac function, and 
symptoms of chronic heart disease, but effects vary 
substantially depending on route, baseline LVEF, cell type, 
and setting. 
4.22 (3.47 to 4.97) RR=0.28 (0.14-0.53) NA 
Henry 2007 5 
Ad5FGF-4 has no overall impact on signs and symptoms in 
patients with refractory angina, but gender differences may 
be present. 
NA NA 10,2 
Hristow 2006 4 
BMSC are associated with improvements in cardiac function 
parameters in patients with AMI. 
4.21 (0.21 to 8.22) NA 5,5 
Ince 2007 5 
G-CSF is not associated with an increase risk of stent 
restenosis or thrombosis in patients with AMI. 
NA NA 2,8 
Jeevanantham 2012 9 
BMSC are associated with improvements in prognosis and 
cardiac fucntion parameters. 
3.96 (2.90 to 5.02) OR=0.39 (0.27 to 0.55) 41,7 
Jiang 2010 9 
Stem cells are associated with improvements in cardiac 
function parameters in patients with AMI. 
2.93 (2.05 to 3.81)   3,5 
Jiang 2012 10 
Intracoronary BMSC are associated with improvements in 
diastolic function parameters and exercise testing features. 
NA NA 0,0 
Kandala 2013 9 
BMSC is associated with improvements in cardiac function 
parameters, especially when administered with 
intramyocardial injection. 
4.48 (2.43 to 6.53) NA 5,1 
Kang 2007 8 
G-CSF is associated with improvements in cardiac function 
parameters in patients with AMI. 
3.46 (0.60 to 6.32) NA 2,6 
Kang 2008 9 
BMSC are associated with improvements in cardiac function 
parameters in patients with AMI. 
2.88 (1.69 to 4.08) NA 6,2 
Kuswardhani 2011 9 
BMSC is associated with improvements in prognosis and 
cardiac function parameters in patietns with AMI. 
3.46 (0.60 to 6.32) NA NA 
Li 2013 10 
Stem cells are associated with improvements in prognosis 
and symptoms. 
NA OR=0.33 (0.08-1.39) 2,4 
Lipinski 2007 10 
BMSC are associated with improvements in prognosis and 
cardiac function parameters in patients with AMI, with 
meta-regression suggesting an association between inject 
cell volume and LVEF change. 
2.97 (1.88 to 4.06) OR=0.52 (0.16-.63) 43,4 
12 
Martin-Rendon 2008 10 
BMSC are associated with improvements in cardiac function 
parameters in patients with AMI. 
2.99 (1.26 to 4.72) RR=0.62 (0.22-1.76) 38,3 
Moazzami 2013 11 
G-CSF is not associated with changes in prognosis, cardiac 
function parameters, or symptoms. 




The effect of BMSC on LVEF is associated with number of 
discrepancies in study reports: studies without discrepancies 
suggest no clinically relevant effect on LVEF. 
2.91 (1.47 to 4.35) NA NA 
Singh 2009 9 
BMSC are associated with improvements in cardiac function 
parameters in patients with AMI. 
6.11 (2.67 to 9.54) NA 4,8 
Sun 2010 9 
Stem cells are associated with improvements in cardiac 
function parameters in patients with AMI. 
NA NA 3,5 
Takagi 2011 6 
Stem cells are not associated with improvements in cardiac 
function parameters in patients with AMI. 
2.87 (1.95 to 3.78) NA 0,3 
Tian 2014 9 
BMSC are associated with improvements in cardiac function 
parameters, especially in subjects with revascularizable 
regions. 
4.91 (2.84-6.99) NA NA 
Wen 2011 9 
BMSC are associated with improvements in cardiac function 
parameters. 
3.83 (2.10 to 5.56) NA 4,1 
Wen 2011 8 
BMSC are associated with improvements in cardiac function 
parameters. 
3.72 (1.98 to 5.46) NA 1,5 
Xu 2014 9 
BMSC are associated with improvements in prognosis and 
cardiac fucntion parameters in patients with chronic IHD 
and HF. 
3.54 (1.92 to 5.17) RR=0.49 (0.29-0.84) NA 
Zhang 2009 9 
BMSC transfer 4-7 days post-AMI is associated with 
improvements in prognosis and cardiac function 
parameters. 
4.63 (1.00 to 8.26) RR=0.33 (0.09-1.22) 5,1 
Zhang 2009 9 
BMSC are associated with improvements in cardiac function 
parameters in patients with AMI. 
4.77 (1.42 to 8.12) NA 3,6 
Zhang 2010 9 
BMSC are associated with improvements in prognosis and 
cardiac fucntion parameters, especially in younger patients 
and those receiving BMSC 6-7 days post-AMI. 
4.37 (2.66 to 6.08) RR=0.33 (0.13-0.89) 2,7 
Zhao 2011 9 
BMSC are associated with improvements in cardiac function 
parameters which may depend on primary intervention, 
route, cell type, and baseline LVEF. 
4.59 (2.22 to 6.95) NA 0,6 
13 
Zimmet 2011 9 
BMSC and G-CSF are associated with improvements in 
prognosis and cardiac function parameters. 
2.70 (1.48 to 3.92) 
for BMSC, and 2.81 
(-1.49 to 7.11) for G-
CSF 
OR=1.16 (0.40-3.57) for BMSC, 
and OR=1.69 (0.19-20.5) for G-CSF 
7,6 
Zohlnhöfer 2008 7 
G-CSF is not associated with changes in cardiac function 
parameters in patients with AMI. 




Figure 1S. Trend in the number of included studies over time. Each square represents a single systematic review. 
 
